Green Cross US FDA OK to test new anti-Parkinsonian drug candidate

Published: 2010-02-12 06:56:00

Updated: 2010-02-12 06:56:00

Green Cross Corporation said on February 10 it has received approval from the U.S. Food and Drug Administration to start an early-stage human trial of GCC1290K for the treatment of Parkinson’s disease.

The company said GCC1290K is a novel neuroprotectant to treat Parkinson’s disease. After ora...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK